These Hedge Funds May Profit From BridgeBio IPO

Viking Global Investors is among the principal shareholders named in BridgeBio’s IPO prospectus.

Illustration by II

Illustration by II

Viking Global Investors and Perceptive Advisors stand to benefit from the planned initial public offering of BridgeBio Pharma, a drug company in Palo, Alto California that was founded in 2015.

Hedge fund firm Viking Global Investors and KKR & Co. each own at least five percent of its shares, according to a preliminary IPO prospectus that BridgeBio filed May 24 with regulators.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.